title: Cephaloridine nephrotoxicity in streptozotocin induced diabetic Fischer 344 (F344) rats.
abstract: The purpose of this study was to determine if cephaloridine nephrotoxicity is attenuated in streptozotocin (STZ)-induced diabetic rats. Fischer 344 (F344) rats (205-250 g) were given a single injection (i.p.) of STZ (27-35 mg/kg) or citrate buffer. The nephrotoxicity of (750 mg/kg) cephaloridine (i.p.) was then compared with normoglycemic and 14-day diabetic rats. Increased blood urea nitrogen (BUN) levels as well as diminished renal cortical slice accumulation of tetraethylammonium (TEA) and lactate-stimulated p-aminohippurate (PAH) were measured (P less than 0.05) in normoglycemic rats 48 h after cephaloridine administration. Cephaloridine failed to alter BUN levels and organic ion accumulation in diabetic rats. Diabetes did not totally protect against cephaloridine toxicity since kidney weights were elevated in normoglycemic and diabetic rats 48 h after administration of 750 mg/kg cephaloridine. A series of experiments also measured BUN levels, kidney weight and renal cortical slice uptake of PAH and TEA 24, 48 and 72 h after (1500 mg/kg) cephaloridine administration. Cephaloridine increased (P less than 0.05) kidney wt and decreased PAH and TEA uptake (P less than 0.05) in the normoglycemic group at 24-72 h. No change in kidney wt, PAH or TEA uptake was observed in the diabetic rats. These data indicate diabetes reduces cephaloridine nephrotoxicity.
authors.affiliation: Department of Pharmacology, Marshall University School of Medicine, Huntington, WV 25755-9310.
authors.forename: M A
authors.initials: MA
authors.lastname: Valentovic
authors.forename: J G
authors.initials: JG
authors.lastname: Ball
authors.forename: C
authors.initials: C
authors.lastname: Elliott
authors.forename: E
authors.initials: E
authors.lastname: Madan
mesh_terms: D000818:Animals; D001786:Blood Glucose; D001806:Blood Urea Nitrogen; D002509:Cephaloridine / Q000633:toxicity*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism* / Q000473:pathology; D006029:Glycosuria; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D011507:Proteinuria; D051381:Rats; D011916:Rats, Inbred F344; D012016:Reference Values; D019789:Tetraethylammonium; D013757:Tetraethylammonium Compounds / Q000378:metabolism; D010130:p-Aminohippuric Acid / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D013757:Tetraethylammonium Compounds; D019789:Tetraethylammonium; D002509:Cephaloridine; D010130:p-Aminohippuric Acid